How has highly active antiretroviral therapy (HAART) altered the incidence of opportunistic GI disorders?
Since the introduction of protease inhibitors and HAART in 1995, there has been a constant and dramatic decline of all GI opportunistic disorders (ODs) in AIDS patients. In addition, HAART has also been shown to indirectly treat many GI ODs. Once the immune status of the patient improves, the OD generally resolves. However, careful follow-up of patients receiving HAART early on is mandatory as their condition can decompensate as a result of immune reconstitution syndrome (IRIS).